Cubist Pharmaceuticals Inc

Cubist Pharmaceuticals — Q3 2004 Earnings Presentation

18 slides from Cubist Pharmaceuticals's earnings presentation, Nov 2, 2004

  1. Slide 1: Serious Infections. Serious Business.

    Serious | Infections. / howe pened or soppee arts pit regan. facxard he aw vacranetnth erp

  2. Slide 2: Comparison of IV Antibiotic Launches

    ‘Cumulative Sales ($000) Comparison of IV Antibiotic Launches cup Cumulative Gross Sales Since Launch (ICS for Cubicin; IMS Non-Retail for others) Cable? Sloe ‘Hino Bm dno Aho Ghee Chao Thee Ghee shine fhe tthne hee ‘how ih wo Seen SS cublin nave SE Syrercid A Rocephin SP SZyc IV] 2

  3. Slide 3: Summary Statement of Operations

    Summary Statement of Operations cube ‘Three months ended ‘September 30, 2004 ‘2003 Cubicin® revenues,net $ 17988 $ - Total revenues 19.425 _- Cost of product revenues 6440 + ‘Other operating expenses 27,910 90,866 Operating loss (14925) (90,865) Other expenses (2,780) @,342) Netloss $ (17.705) $(94.

  4. Slide 4: Our Passion for Serious Business

    -QUR PASSION 8 TON =... ous Business,

  5. Slide 5: Increases in U.S. MRSA Rates

    Increases in U.S. MRSA Rates cube Propotin ofS. aureus Nosocomial ifections Resistant to Oxacilin (MRSA) Among ICU Patients —1cu = Non Icu s+ Community Estimates (TX) Percent Resistance 1989 1991 1993 1995 1997 1999 2001 2003 Sources: NNIS System, datafor2003 ae nconpiete YEA

  6. Slide 6: DMC Reports

    DMC Reports cube + September 2003 - “continue study” + March 2004 - “continue study” + July 2004 (over 100 patients) ~ “continue study” + October 2004 (over 136 patients) - “continue study” 6

  7. Slide 7: Pipeline

    Pipeline sere Strategic Focus estentens Serious and Life-Threatening Infections Discovery Research r novel

  8. Slide 8: Comparison of IV Antibiotic Launches

    ‘Cumulative Sales ($000) Comparison of IV Antibiotic Launches cup Cumulative Gross Sales Since Launch (ICS for Cubicin; IMS Non-Retail for others) Cable? Sloe ‘Hino Bm dno Aho Ghee Chao Thee Ghee shine fhe tthne hee ‘how ih wo Seen SS cublin nave SE Syrercid A Rocephin SP SZyc IV] 3

  9. Slide 9: Summary Statement of Operations

    Summary Statement of Operations cube ‘Three months ended ‘September 30, 2004 ‘2003 Cubicin® revenues,net $ 17988 $ - Total revenues 19.425 _- Cost of product revenues 6440 + ‘Other operating expenses 27,910 90,866 Operating loss (14925) (90,865) Other expenses (2,780) @,342) Netloss $ (17.705) $(94.

  10. Slide 10: Cubicin Customers

    Cubicin® Customers cuBist Cumulative Number of Unique Customers " 2,000. 221} 394 2003 1004 2004 3Q04 10

  11. Slide 11: Orders vs. Re-orders

    Orders vs. Re-orders CUBIS ys eres | ‘Approximately 2,800 unique ‘customers through 3 7% ats ee as 21H nd 2003 nd at 2004 nd 2 2004 End 03 2004 u

  12. Slide 12: Customers Ordering per Day

    Hof Customers Ordering per Day (5 Day Average) Cubicin® New vs. Repeat Accounts L . PPL PLO LLL. UC CEE EE EE

  13. Slide 13: Cubicin Vials: Orders and Re-Orders

    Cubicin® Vials Orders and Re-Orders CUBIST Re-Order Rates (10 Day Average) 2 2x ‘6 15x Oe PO ELPEEPEE EP ELE! Vials /Order a Fore) —Uinar we Matas orger) 8

  14. Slide 14: Account Ordering Trends

    Account Ordering Trends cup Vials per Account 10 Nov.09 Dec-03 Jan-04 Feb-04 Mar.04 Apr-04- MayO4 Jun04 Jubod Auy-01 Sepad Aen co Note: Caladatons include ony ose account that ordet each gven month f Source: Updated Order Summary (through 10222004)

  15. Slide 15: Penetration and Formulary Approvals

    Penetration and Formulary Approvals by Type of Account Account Potential Customers % of Potential % Formulary Type | Customers | Ordering | Customers Approval (9730/04) Ordering (10118104) (9730/04) A 324 m2 86% 61% B 546 434 77% 50% c 834 408 48% 17% DIO 7,149 1,694 23% 3% Total 8.853 2,808 31% 1%

  16. Slide 16: Non-Retail Sales — Cubicin Market

    Non-Retail Sales — Cubicin® Market CUBIST ‘Non-Retal Sales $ - Rolling Quarters sao soon = fecusen : Inseussvaruencs| oe lovancowvens losreRcio 60m lazvvox w lezwox ona stom som sone’ are Fetters hoa sept 16 Soutce: MS Non-Reta, NOC

  17. Slide 17: Summary Statement of Operations

    ‘Three months ended Summary Statement of Operations ‘September 30, 2004 ‘2003 Cubicin® revenues,net $ 17988 $ - Total revenues 19.425 _- Cost of product revenues 6440 + ‘Other operating expenses 27,910 90,866 Operating loss (14925) (90,865) Other expenses (2,780) @,342) Netloss $ (17.705) $(94.208)

  18. Slide 18: Searchable text section of graphics shown above

    Searchable text section of graphics shown above Ser ious infections. [GRAPHIC] [LOGO] Serious Business. Statements made during this presentation that are not historical fact may be forward-looking statements that are subject to a variety of risks and uncertainties. There are a number of important fa

Cubist Pharmaceuticals — Q3 2004 Earnings Presentation on 6ix